<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244009</url>
  </required_header>
  <id_info>
    <org_study_id>MK-4827-002</org_study_id>
    <nct_id>NCT01244009</nct_id>
  </id_info>
  <brief_title>A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)</brief_title>
  <official_title>A Phase II Efficacy Study of MK-4827 in Patients With Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy and safety of MK-4827 in participants with relapsed
      mantle cell lymphoma (MCL) and in a subset of participants with inactivation of the
      Ataxia-Telangiectasia Mutated (ATM) gene.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who have a complete response (CR) or partial response (PR) during the study</measure>
    <time_frame>Tumor assessments will be performed every 9 weeks for the first year the participant is on treatment, every 12 weeks in year 2, and every 6 months in year 3 and beyond</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with adverse events</measure>
    <time_frame>From the day of enrollment through 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from allocation to disease progression or death from any cause (Progression-free survival)</measure>
    <time_frame>Tumor assessments will be performed every 9 weeks for the first year the participant is on treatment, every 12 weeks in year 2, and every 6 months in year 3 and beyond</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <condition>Mantle-Cell</condition>
  <arm_group>
    <arm_group_label>MK-4827</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-4827</intervention_name>
    <description>MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.</description>
    <arm_group_label>MK-4827</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Participant must have a diagnosis of MCL that has relapsed after at least one prior
             chemotherapy regimen or for which the participant has refused standard therapy

          -  Participant has measureable disease defined by lymphadenopathy, organomegaly, bone
             marrow involvement and/or circulating lymphoma cells. At least one lesion must be &gt; 2
             cm in the longest diameter and measurable in 2 perpendicular dimensions

          -  Participant has a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology
             Group (ECOG) Performance Scale

          -  Female participants of child-bearing potential agree to use two approved contraceptive
             methods or remain abstinent throughout the study

          -  Male participants agree to use an adequate method of contraception throughout the
             study

          -  Participant has no history of prior cancer except certain cervical, skin, or prostate
             cancers, or has undergone potentially curative therapy with no recurrence for five
             years, or is deemed at low risk for recurrence

          -  Participant has not had any platelet or red blood cell transfusions or colony
             stimulating factor support during the month prior to treatment

          -  Participant has a pre-study diagnostic formalin fixed paraffin-embedded tumor tissue
             sample available

        Exclusion Criteria :

          -  Participant has had chemotherapy, radiotherapy, or biological therapy within 4 weeks
             of screening

          -  Participant has a history of central nervous system (CNS) lymphoma

          -  Participant requires the use of corticosteroids

          -  Participant is pregnant, breastfeeding, or expecting to conceive or father children
             during the study

          -  Participant is known to be human immunodeficiency virus (HIV)-positive

          -  Participant has a history of Hepatitis B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <name_title>Vice President of Late Stage Development</name_title>
    <organization>Merck Sharp &amp; Dohme Corp</organization>
  </responsible_party>
  <keyword>Poly (ADP-ribose) polymerase (PARP) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

